Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice

Choi, Kunhee; younsun, Lee; Kim, Wonkyun; Kim, Seung Jung; Shin, Kyong‐Oh; Yu, Ji‐Yeon; Lee, Mi Kyeong; Lee, Young Moo; Hong, Jin Tae; Yun, Young Won; Yoo, Hwan‐Soo

doi:10.1016/j.jnutbio.2013.10.007

Cited by 145 publications

(124 citation statements)

References 31 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…Interestingly, we also found that ginkgolide B did not decrease TG levels in serum. Other studies have yielded similar findings [35]. We speculate that excess lipids may be broken down and discharged via feces or urine and expect to continue to analyze the metabolites by metabolomics techniques in the future.…”

Section: Discussionsupporting

confidence: 71%

WITHDRAWN: Ginkgolide B reduces hepatic lipid accumulation and ameliorates nonalcoholic fatty liver disease in high-fat dietâ€“induced obese mice

Wang¹,

Liou²,

Wu³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Ginkgolide B is isolated from Ginkgo biloba leaves. It has multiple biological functions, including alleviating lung injury and ischemic stroke in mice and protecting pancreatic beta cells and improving endothelial dysfunction in diabetic mice. Here we sought to determine whether ginkgolide B ameliorates nonalcoholic fatty liver disease (NALFD) in high-fat diet (HFD)-induced obese mice. We also evaluated whether or not ginkgolide B reduces lipid accumulation of hepatocytes in vitro. C57BL/6 mice were fed with HFD and treated with ginkgolide B by intraperitoneal injection twice a week for last 10 weeks of the 14-week HFD feeding period. In addition, HepG2 cells were treated with oleic acid to establish a fatty liver cell model and exposed to various concentrations of ginkgolide B. Ginkgolide B significantly decreased hepatic lipid accumulation and alleviated steatosis in HFD-induced obese mice. It also reduced body weight and epididymal adipose tissue weight. Serum assay results showed that ginkgolide B inhibited leptin, alanine aminotransferase, and aspartate aminotransferase levels and increased HDL levels compared to obese mice. It also decreased fatty acid synthase expression and increased Sirt-1 and phosphorylation of AMP-activated protein kinase α in liver tissue. Furthermore, ginkgolide B significantly inhibited lipid accumulation and expression of adipogenesis-related proteins and increased adipolysis-associated protein expression in hepatocytes in vitro. These results suggest that ginkgolide B is an effective natural compound for alleviating hepatic lipid accumulation and reducing body weight in obese mice. It also ameliorated NALFD in HFD-induced obese mice. www.impactjournals.com/oncotarget/

show abstract

Section: Discussionsupporting

confidence: 71%

WITHDRAWN: Ginkgolide B reduces hepatic lipid accumulation and ameliorates nonalcoholic fatty liver disease in high-fat dietâ€“induced obese mice

Wang¹,

Liou²,

Wu³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…PPARγ up-regulation has been linked to exacerbated steatosis by the mechanism involving the activation of lipogenic genes and de novo lipogenesis and increased hepatic TG (MoranSalvador et al 2011). Recently, down-regulation of PPARγ by SF in adipocytes was confirmed by Choi et al (2012Choi et al ( , 2014. In our trial, the TG levels in blood serum were not altered, however, the TG content in the liver was decreased after the administration of both SF doses (Figure 1).…”

Section: Discussionsupporting

confidence: 64%

“…Leptin production is positively correlated with obesity, while adiponectin production is inversely related to it (Choi et al 2014). Choi et al (2014) showed that SF in the high fat diet (HFD) rats significantly attenuated the induced increases in leptin expression and increased the HFD-induced reduction in adiponectin expression. In our doi: 10.17221/8665-CJAS healthy rats, in the in vivo trial, adiponectin was unchanged.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, there is still limited information regarding SF as a nutraceutical source for the protection or management of pandemic levels of worldwide diseases like diabetes and hypertension by its influence on carbohydrate, lipid homeostasis in organs like pancreas, liver, adipocyte tissue. Some recent studies in clinical, animal, and in vitro models suggested SF antidiabetic properties (Choi et al 2012(Choi et al , 2014De Souza et al 2012;Lee et al 2012;Bahadoran et al 2013) as well as cardiovascular and antihypertensive protection (Shan et al 2010;Bahadoran et al 2012a;Senanayake et al 2012;Bai et al 2013). Potential efficacy of SF makes it even a good choice for supplementary treatment in type 2 diabetes for normalization of changes in blood glucose and insulin sensitivity (Bahadoran et al 2012b(Bahadoran et al , 2013.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute sulforaphane action exhibits hormonal and metabolic activities in the rat: in vivo and in vitro studies

Okulicz¹,

Hertig²

2016

CZECH J ANIM SCI

View full text Add to dashboard Cite

So far, only the chronic effect of sulforaphane (SF) on metabolism was examined. This study sheds more light on SF potential ability of regulating lipid, carbohydrate, and hormonal metabolism during its acute action in in vivo and in vitro conditions. In the in vivo trial, rats were given once intragastrically 10 or 20 mg/kg of SF and were decapitated 4 h after the single intragastric treatment. The serum and the liver were collected to assay lipid, carbohydrate, and hormonal parameters. Additionally, we evaluated the acute direct in vitro action of SF (1.5 h) on basal and insulin-stimulated lipogenesis and basal and epinephrine-induced lipolysis in isolated primary rat adipocytes at 1µM, 10µM, and 100µM concentrations. The SF hormonal action was dose-dependent. In the in vivo trial, the higher dose evoked a significant insulin release (P ≤ 0.01) and showed a tendency to limit the secretion of leptin from adipocytes compared with the control animals. Surprisingly, two applied SF doses did not cause any changes in serum glucose level and liver glycogen content. Both SF doses reduced HDL-and increased LDL-cholesterol level (P ≤ 0.05), evoked a drop of liver triacylglycerol content (P ≤ 0.05) compared with the control rats. In the in vitro study, only 100µM SF evoked elevation of basal-and epinephrine-induced lipolysis and inhibition of basal-and insulin-induced lipogenesis in comparison with the control (P ≤ 0.001). SF adipocyte influence was independent of epinephrine and insulin action. Recapitulating, SF exhibited a tendency towards limiting lipid synthesis in adipocytes as well as in the liver, possibly via Nrf2 pathway. The disturbance in the LDL-to HDL-cholesterol ratio and dose-dependent increase in insulin concentration at normal glycaemia were connected probably with the SF capability to generate temporarily ROS in the pancreas and in the vascular endothelial cells in in vivo trials.

show abstract

“…Sulforaphane, an aliphatic isothiocyanate present in cruciferous vegetables such as broccoli, cauliflower and cabbage, is known for its association with adipocytes and has been shown that can inhibit Dnmt1, 3A and histone deactylases activity [97]. Dietary intervention on sulforaphane suggest an anti-obesity activity by inhibiting adipogenesis and suppressing lipogenesis [121]. An anti-obesity effect with reduction of body weight and abdominal obesity was also found in dietary intervention with resveratrol, present in red grapes [122], playing a role in epigenetic changes [123].…”

Section: Walking To An Epigenetic Food?mentioning

confidence: 99%

Epigenetics of Human Obesity: A Link Between Genetics and Nutrition

Albuquerque

Manco

Nóbrega

2014

Molecular Mechanisms Underpinning the Development of Obesity

View full text Add to dashboard Cite

Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice

Cited by 145 publications

References 31 publications

WITHDRAWN: Ginkgolide B reduces hepatic lipid accumulation and ameliorates nonalcoholic fatty liver disease in high-fat dietâ€“induced obese mice

WITHDRAWN: Ginkgolide B reduces hepatic lipid accumulation and ameliorates nonalcoholic fatty liver disease in high-fat dietâ€“induced obese mice

Acute sulforaphane action exhibits hormonal and metabolic activities in the rat: in vivo and in vitro studies

Epigenetics of Human Obesity: A Link Between Genetics and Nutrition

Contact Info

Product

Resources

About